Jennifer Robinson
Contatto Relazioni con gli Investitori presso VERVE THERAPEUTICS, INC.
Profilo
Jennifer Robinson is currently the Vice President of Investor Relations & Communications at Verve Therapeutics, Inc. Prior to her current position, she worked as the Senior Director of Investor Relations at Dyax Corp.
from 2014 to 2016, and as the Senior Director of Investor Relations at Ra Pharmaceuticals, Inc. and resTORbio, Inc. She also served as the Vice President of Investor Relations & Communications at Deciphera Pharmaceuticals, Inc. Ms. Robinson received her undergraduate degree from Dartmouth College.
Posizioni attive di Jennifer Robinson
| Società | Posizione | Inizio |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | - |
Precedenti posizioni note di Jennifer Robinson
| Società | Posizione | Fine |
|---|---|---|
| DYAX CORP. | Contatto Relazioni con gli Investitori | 01/04/2016 |
| RA PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - |
| DECIPHERA PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - |
| ADICET BIO, INC. | Contatto Relazioni con gli Investitori | - |
Formazione di Jennifer Robinson
| Dartmouth College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jennifer Robinson
